Evaluation of treatment benefit: Randomized controlled trials and population-based observational research

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3298-3299

  Booth, Christopher M ^a   Tannock, Ian F ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER THERAPY; CHRONIC TOXICITY; CLINICAL EFFECTIVENESS; EXPERIMENTAL THERAPY; GOLD STANDARD; HUMAN; LETTER; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; TREATMENT OUTCOME; EVALUATION STUDY; NOTE;

EVALUATION STUDIES AS TOPIC; HUMANS; TREATMENT OUTCOME;

EID: 84891518400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5023     Document Type: Letter

References (12)

1. Goodwin PJ, Ballman KV, Small EJ, et al: Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol 31:1123-1124, 2013.
2. Seruga B, Sterling L, Wang L, et al: Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29:174-185, 2011.
3. Altwairgi AK, Booth CM, Hopman WM, et al: Discordance between conclusions stated in the abstract and conclusions in the article: Analysis of published randomized controlled trials of systemic therapy in lung cancer. J Clin Oncol 30:3552-3557, 2012.
4. Vera-Badillo FE, Shapiro R, Ocana A, et al: Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24:1238-1244, 2013.
5. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448- 4456, 2006. (Pubitemid 46630983)
6. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013.
7. Wu XC, Lund MJ, Kimmick GG, et al: Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30:142- 150, 2012.
8. Landrum MB, Keating NL, Lamont EB, et al: Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer 118:3345-3355, 2012.
9. Kankesan J, Shepherd FA, Peng Y, et al: Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small cell lung cancer: A population-based study. Curr Oncol 20:30-37, 2013.
10. Hershman D, Hall MJ, Wang X, et al: Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107:2581-2588, 2006. (Pubitemid 44845611)
11. Lohrisch C, Paltiel C, Gelmon K, et al: Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 24:4888-4894, 2006. (Pubitemid 46630916)
12. Birkmeyer JD, Stukel TA, Siewers AE, et al: Surgeon volume and operative mortality in the United States. N Engl J Med 349:2117-2127, 2003. (Pubitemid 37464537)